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The phenotypic and strain-related properties of human prion diseases are, according to the prion hypothesis,
proposed to reside in the physicochemical properties of the conformationally altered, disease-associated
isoform of the prion protein (PrPSc), which accumulates in the brains of patients suffering from Creutzfeldt-
Jakob disease and related conditions, such as Gerstmann-Straussler-Scheinker disease. Molecular strain
typing of human prion diseases has focused extensively on differences in the fragment size and glycosylation
site occupancy of the protease-resistant prion protein (PrPres) in conjunction with the presence of mutations
and polymorphisms in the prion protein gene (PRNP). Here we report the results of employing an alternative
strategy that specifically addresses the conformational stability of PrPSc and that has been used previously to
characterize animal prion strains transmitted to rodents. The results show that there are at least two distinct
conformation stability states in human prion diseases, neither of which appears to correlate fully with the
PrPres type, as judged by fragment size or glycosylation, the PRNP codon 129 status, or the presence or absence
of mutations in PRNP. These results suggest that conformational stability represents a further dimension to
a complete description of potentially phenotype-related properties of PrPSc in human prion diseases.
Transmissible spongiform encephalopathies (TSE) are fatal
neurological diseases that occur in farmed and free-ranging
animals, including scrapie in sheep and goats, transmissible
mink encephalopathy, bovine spongiform encephalopathy in
cattle, and chronic wasting disease in deer and elk (4, 52).
Sheep scrapie is the prototypic animal TSE and has been
investigated for many years in the form of rodent-adapted
isolates that have given rise to distinct stable laboratory strains
(6). Despite intensive investigation, there is little or no direct
evidence for a unique foreign nucleic acid genome associated
with scrapie infectivity, and the paradigm most frequently in-
voked to explain TSE is that of transmissible amyloidosis (ev-
idence reviewed in references 8 and 46). This protein-only or
prion hypothesis proposes that the infectious agent or prion is
an altered form (termed PrPSc [disease-associated isoform of
the prion protein]) of the host-encoded prion protein (PrPC),
which is produced by a posttranslational conversion involving
rearrangements of secondary (increased -sheet content) and
quaternary (self-aggregation) structure (41). Polymorphisms in
the host prion protein gene in part determine susceptibility to
infection and modify the resultant disease phenotype, but in
order to explain the existence of distinct strains, PrPSc has been
proposed to exist in different, stable, and replicative biophys-
ical forms or “conformers” that “encipher” strain-like proper-
ties (reviewed in references 1 and 11). Recent reports of the
successful production of prion infectivity with distinct struc-
tural and biological properties, from recombinant PrP, strongly
support the prion hypothesis in general and the structural
variant hypothesis in particular (9, 23–28, 51).
The concept of molecular strain typing has acquired consid-
erable currency in the identification and diagnosis of human
prion diseases. Three major clinicopathological phenotypes of
human prion disease are recognized (reviewed in reference
17): Creutzfeldt-Jakob disease (CJD), Gerstmann-Straussler-
Scheinker disease (GSS), and fatal insomnia (FI). CJD may be
acquired, in the case of variant CJD (vCJD) obtained from
bovine spongiform encephalopathy (BSE)-infected cattle, may
occur in association with mutations in the human prion protein
gene (PRNP) as familial CJD, or may occur in a sporadic
fashion (sporadic CJD [sCJD]), perhaps due to rare stochastic
events leading to PrPSc formation and accumulation. FI occurs
sporadically (sporadic FI [sFI]) or in association with the
D178N PRNP mutation (fatal familial insomnia [FFI]), and
GSS is associated with a series of pathogenic mutations in
PRNP, the most common of which is P102L (reviewed in ref-
erence 17).
PrPSc analysis in this context has relied heavily on the bio-
physical differences in PrPSc, as determined by limited prote-
olysis of postmortem human prion disease brain samples and
analysis of the protease-resistant core of PrPSc (termed PrPres
or PrP27-30) size by Western blotting (10, 32). Three major
conformational states have been inferred from the observation
of 21-kDa (type 1), 19-kDa (type 2), or 7- to 8-kDa PrPres.
Variable glycosylation site occupancy adds to this diversity (10,
14, 33), as follows: PrPres types are given the suffix “A” if
mono- or nonglycosylated PrPres predominates or “B” if
diglycosylated PrPres predominates (33). These parameters
have diagnostic value in that sCJD cases are marked by type 1
and/or type 2A PrPres, vCJD has type 2B PrPres, and two
different pathological phenotypes in GSS are associated with
either type 1 or 7- to 8-kDa PrPres (13, 34, 35, 39). Moreover,
the clinicopathological variation between different cases of
sCJD appears to correlate to a large extent with the relative
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mixture of type 1 and type 2A PrPres in combination with the
patient’s PRNP codon 129 polymorphic status (MM, MV, or
VV) (7, 36).
These observations provide a correlation between PrPSc
types and human disease phenotype, consistent with different
prions underlying different prion diseases, but the Western
blotting approach is indirect, of relatively low sensitivity, and
likely to be an incomplete description of PrPSc. An alternative
approach to defining PrPSc, termed the conformation-depen-
dent immunoassay (CDI), depends upon the effect of increas-
ing concentrations of the chaotropic salt guanidine hydrochlo-
ride (GdnHCl) to unmask epitopes in PrP that become hidden
during the structural rearrangements involved in PrPSc forma-
tion (43). CDI has shown that up to 90% of the PrPSc present
in a sCJD brain is susceptible to proteolysis and would there-
fore not figure in conventional Western blot typing assays (44).
Moreover, the stability profiles of PrPSc, as defined by unmask-
ing of the monoclonal antibody 3F4 epitope, have been re-
ported to be unique for a series of well-characterized scrapie
strains in hamsters (43). A related assay, termed the confor-
mation stability assay (CSA), has also been developed (37), in
which conformational stability is measured as a function of the
resistance to proteolysis following exposure to increasing con-
centrations of GdnHCl. Rodent-adapted prion strains that
were indistinguishable by electrophoretical mobility of PrPres
can be distinguished by CSA when the stability of PrPres is
expressed as the concentration of GdnHCl required to make
half of the protein susceptible to proteolytic degradation
(GdnHCl1/2) (37, 38). Given the growing realization that PrP
Sc
stability may be a strain-related property, we have asked
whether there are consistent differences in human PrPSc sta-
bility between different human prion diseases, and whether any
such differences correlate with currently used parameters, such
as PrPres fragment size, PrPres glycosylation site occupancy,
and codon 129 status.
MATERIALS AND METHODS
Human brain materials. Thirteen variant CJD (vCJD) cases, fourteen spo-
radic CJD (sCJD) cases, two GSS cases with P102L mutations, and five control
(non-CJD) cases with other neurological diseases were analyzed in this study.
Cases were selected based on the availability of autopsy-collected frozen brain
specimens with consent for research use. Appropriate ethical approval was ob-
tained (LREC 2000/4/157). All cases used were of United Kingdom origin. Brain
tissue from each case had been examined both histopathologically and biochem-
ically, and a definite diagnosis had been reached by established criteria (5, 16).
The codon 129 polymorphism of the PRNP of each case was determined by
restriction fragment length polymorphism (30). The protease-resistant core frag-
ments of PrPSc (PrPres) found in brain was classified as type 1, 2A, or 2B as
previously described according to the nomenclature of others (13, 35). Among
the 14 sporadic CJD cases, 13 cases were of the MM1 subtype, and 1 case had a
VV2 subtype. One GSS case showed the typical three PrPres bands (type 1),
whereas the other GSS case had only proteinase K (PK)-resistant fragments of
8 kDa. Among the five neurological control cases, three cases were of the MM
genotype at codon 129 of PRNP (with diagnoses of vascular dementia, motor
neurone disease, and B-cell lymphoma), one case was of the MV genotype (with
a diagnosis of vascular dementia), and one case was of the VV genotype (with a
diagnosis of dementia with Lewy bodies). In all instances, the tissue analyzed was
gray matter-enriched frontal cortex (FC), and additionally, cerebellar cortex
(Cb) and thalamus (Th) in vCJD cases, taken from frozen half-brain specimens.
Preparation of brain tissue. Brain tissue homogenates were prepared in nine
volumes (wt/vol) of phosphate-buffered saline (PBS), pH 7.4, containing 2%
Sarkosyl by two cycles of homogenization in the FastPrep instrument (Qbio-
gene). The homogenized brain samples were stored at 80°C until use.
Enrichment of disease-associated PrP. The 10% homogenates were diluted to
5% (wt/vol) using PBS containing 2% (wt/vol) Sarkosyl and were incubated for
10 min at room temperature on a shaking platform. The samples were then
centrifuged at 500  g for 5 min at 20°C, and the supernatants were collected.
For the enrichment of the disease-associated isoform of PrP, 100-l aliquots of
cleared brain homogenates in PBS containing 2% Sarkosyl were centrifuged at
20,800 g for 1 h at 4°C as described previously (48, 50). After careful aspiration
of the supernatants, pellets containing a detergent-insoluble fraction of PrP were
used for GdnHCl-induced denaturation. In some cases, pellets were resuspended
at the starting volume using homogenization buffer in order to investigate the
effect of this method of enriching PrPSc.
CDI. The CDI method used in this study was based on an enzyme-linked
immunosorbent assay (ELISA)-formatted, time-resolved fluorometry CDI as
described previously (2, 43). Samples prepared in 2% Sarkosyl in PBS were
divided into the following two parts: one part was mixed with the same volume
of PBS containing Complete EDTA-free protease inhibitors (native sample [N]),
and the other part was mixed with the same volume of 8 M GdnHCl and
incubated for 6 min at 81°C (denatured sample [D]). Both N and D were
adjusted using distilled water containing EDTA-free protease inhibitors to a final
concentration of GdnHCl of 0.35 M. A 96-well black polystyrene plate (Fisher)
was coated with 2 g/well anti-PrP antibody MAR-1 (CSL Behring, Marburg,
Germany) overnight at room temperature. MAR-1 specifically recognizes human
PrP with a correctly formed disulfide bridge. After removal of excess antibody,
the plate was washed four times with wash buffer (PerkinElmer) and then
saturated with 0.5% (wt/vol) bovine serum albumin (BSA) and 6% (wt/vol)
sorbitol in wash buffer for 1 h at room temperature on a plate shaker. After the
plate was washed four times with wash buffer, prepared samples were loaded in
duplicate or triplicate onto the plate (200 l/well). After incubation of the plate
for 2 h at room temperature with shaking, the plate was washed as done previ-
ously. The detection of bound PrP was achieved by the Europium (Eu)-labeled
MAb 3F4, recognizing amino acids 109 to 112 of human PrP. The detector
antibody diluted in assay buffer (PerkinElmer) at 50 ng/ml was added to each
well, followed by incubation for 2 h at room temperature on a plate shaker. The
plate was developed after six washes by 5 min of incubation in enhancement
solution (PerkinElmer) at room temperature. The time-resolved fluorescence
(TRF) signal, measured by cps (counts per seconds), was made using a Victor 2
fluorometer (PerkinElmer).
Western blot analysis. In this study, polyacrylamide gel electrophoresis was
performed using NuPAGE Novex gel system (Invitrogen) as described previously
(54). Samples were digested with PK at 37°C for 1 h, and the PK activity was
terminated by adding Pefabloc to a final concentration of 1 mM. Undigested or
PK-digested samples were mixed with NuPAGE LDS sample buffer to a final
concentration of 1. In some cases, pellets were resuspended with 2 sample
buffer. The samples were incubated for 10 min at 100°C and then separated on
10% Bis-Tris NuPAGE gels. The separated proteins were transferred to poly-
vinylidene difluoride (PVDF) membranes and then were blocked for 1 h with 5%
(wt/vol) nonfat dry milk in TBS-T (20 mM Tris-HCl, pH 7.4; 150 mM NaCl; 0.1%
Tween 20). The immunodetection of PrP was achieved using the MAb 3F4
(Dako) at a final concentration of 75 ng/ml IgG for 1 h. The membrane was
washed three times with TBS-T and incubated with horseradish peroxidase-
conjugated anti-mouse IgG F(ab)2 fragments (Amersham) at a dilution of
1:40,000 for 1 h. Following five washes in TBS-T, blots were developed with ECL
Plus reagent (Amersham) and then exposed to Hyperfilm ECL (Amersham) for
periods of 30 s to 30 min. In some cases, developed membranes were scanned on
a Storm 860 scanning fluorometer. The molecular weight of PrP was determined
by reference to IgG-binding MagicMark XP Western protein standards (Invitro-
gen). Quantitative analysis of the blots was performed using a GS-800 imaging
densitometer and Quantity One software (Bio-Rad Laboratories). For the quan-
tification of images visualized by Storm 860, ImageQuant software (Molecular
Dynamics) was used.
Denaturation transition of PrPC and PrPSc in CDI. The stability of PrPSc in
brain homogenates or the detergent-insoluble pellet fractions of the homoge-
nates was determined by treatment with GdnHCl at different concentrations as
described previously (37, 43). The 10% brain homogenates were mixed with an
equal volume of 2% Sarkosyl in PBS and incubated for 10 min at room temper-
ature. After clarification at 500  g for 5 min, aliquots of the supernatant were
mixed with GdnHCl, with final concentrations ranging from 0 M to 7 M. Alter-
natively, the detergent-insoluble pellets were resuspended in a solution contain-
ing GdnHCl at various concentrations (range, 0 to 7 M). Samples containing
different amounts of GdnHCl were incubated overnight at room temperature on
a shaking platform and were then adjusted using distilled water containing
EDTA-free protease inhibitors to a final concentration of GdnHCl of 0.35 M.
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The extent of unfolding of PrPSc exposed to different concentrations of GdnHCl
was measured in triplicate by CDI.
CDI D/N ratio. TRF counts obtained with CDI were used to generate a D/N
ratio (2, 43). The folding state of PrPSc induced by overnight incubation at 7 M
GdnHCl or by incubation at 81°C in the presence of 4 M GdnHCl was taken to
be full denaturation (42, 43). The D/N ratios were obtained by dividing TRF
counts of denatured samples (D) by the counts of the corresponding native
samples (N; no GdnHCl).
Determination of the denatured fraction of PrPSc. CDI results obtained with
PrPSc-enriched pellets were used to determine the denatured fraction of PrPSc
after an overnight incubation with particular concentrations of GdnHCl. For this,
TRF counts obtained from an aliquot incubated in the absence of GdnHCl (no
GdnHCl) were firstly subtracted from those obtained from aliquots treated with
GdnHCl at various concentrations. Then, the denatured fraction of PrPSc at a
particular concentration of GdnHCl was expressed as a relative value (percent-
age) of TRF counts at that concentration against the counts at 7 M GdnHCl and
was plotted against the corresponding concentrations of GdnHCl. The denatured
fraction of PrPSc (percentage) was calculated as follows: (TRFx M GdnHCl 
TRF0 M GdnHCl/TRF7 M GdnHCl  TRF0 M GdnHCl)  100.
Conventional CSA. For the study of the stability of PrPres against GdnHCl-
induced denaturation, aliquots of the 10% brain homogenates prepared in PBS
were mixed with an equal volume of GdnHCl, giving a range of guanidine
concentrations (0.0 M to 4.0 M) (37). After 2 h of incubation of the mixtures at
room temperature with shaking, samples were adjusted to a final concentration
of 0.4 M GdnHCl in Tris buffer (10 mM Tris-HCl [pH 7.4], 0.5% NP-40, and
0.5% sodium deoxycholate) and then digested with PK at 20 g/ml for 1 h at
37°C. PK activity was terminated by adding Pefabloc at a final concentration of
1 mM. Proteins were then precipitated by mixing the samples with 5 volumes of
prechilled methanol and incubated at 80°C overnight. Samples were then
centrifuged at 16,000  g for 30 min at 4°C, and the supernatants were carefully
aspirated. The remaining pellets were resuspended with 25 l of 2 LDS buffer
and boiled for 10 min. Proteins were analyzed by Western blotting as described
above. The conformation stability assay (CSA) included samples processed in
parallel but unexposed to the chaotropic salt and analyzed by Western blotting
with and without prior PK treatment.
Data presentation and statistics. All graphs were constructed in Microsoft
Office Excel, and statistical analysis employed the Student t test (TTest work-
sheet function) in this same program. P values of less than 0.05 were considered
significant.
RESULTS
The effect on 3F4 epitope exposure by concentration-depen-
dent guanidine denaturation was assayed in homogenates of
the frontal cortex obtained from three cases of variant CJD,
three cases of sporadic CJD (MM1 subtype), and three other
neurological disease (non-CJD) cases. As expected, the results
showed progressive 3F4 epitope exposure by increasing the
guanidine concentration in all CJD cases but full or nearly full
exposure in the non-CJD cases, even at low guanidine concen-
trations. The results were found to vary between cases, irre-
spective of whether they were normalized using the 7 M gua-
nidine value, which was regarded as providing complete
exposure (100%), with the counts presented as relative TRF
(percentage) (Fig. 1A to C), or whether the data were pre-
sented as D/N ratios, with the 0 M guanidine reading given a
value of 1.0 (data not shown). The reason for this variability
was not clear. However, a possible cause was considered to be
that autopsy human brain specimens vary in the absolute and
relative abundances of PrPC and PrPSc and that this has a
confounding effect on CDI. We reasoned that the removal of
PrPC might be necessary before meaningful guanidine-induced
denaturation curves could be obtained for autopsy human
brain specimens.
In order to explore this possibility and more directly inves-
tigate the guanidine-induced structural transition of PrPSc in
the CJD brain, we exploited the known Sarkosyl insolubility of
PrPSc. Preliminary characterization of the Sarkosyl-soluble su-
pernatant and Sarkosyl-insoluble pellet fractions showed that
90% of PrP detected by 3F4 CDI under nondenaturing con-
ditions was in the supernatant fraction (Fig. 2A), whereas
elevated D/N ratios were largely a feature of the variant and
sporadic CJD Sarkosyl-insoluble fractions (Fig. 2B). The char-
FIG. 1. Change in CDI TRF counts following exposure to increas-
ing concentrations of GdnHCl. Brain homogenates from the frontal
cortex were treated with increasing concentrations of GdnHCl (range,
0 to 7 M) and measured by CDI. Three cases each from neurological
control (A), vCJD (B), and sCJD subtype MM1 (C) were analyzed.
Each symbol (squares, diamonds, and triangles) represents individual
cases of each phenotype. TRF counts at particular concentrations of
GdnHCl were expressed as relative values (percentages) to those at 7
M GdnHCl. Data shown represent the average values  SD for trip-
licate wells except for one control case (diamonds in panel A, duplicate
wells). The non-CJD cases presented were all of the PRNP codon 129
MM genotype.
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acterizations of the supernatant comprised of PrPC and the
pellet comprised of PrPSc (as determined by 3F4 accessibility/
inaccessibility) were not absolute. The Sarkosyl-insoluble pel-
let in variant and sporadic CJD cases had higher levels of
3F4-accessible PrP than the non-CJD cases (Fig. 2A), and
there was an elevated D/N ratio in the sporadic CJD superna-
tant compared to those in the supernatants of the non-CJD
cases (Fig. 2B). Further investigation of PrP partitioning by
Sarkosyl solubility showed that Sarkosyl-soluble PrP in variant
and sporadic CJD cases was largely protease sensitive and that
the Sarkosyl-insoluble material contained readily detectable
protease-resistant PrP (Fig. 2C). These studies confirmed that
the form of PrP in the Sarkosyl-insoluble pellet was predomi-
nantly abnormal prion protein, as determined by the criteria of
conformation (PrPSc) and protease resistance (PrPres).
This Sarkosyl-insoluble fraction was then used for CDI to
investigate whether there were any differences in the guani-
dine-induced transition of PrP between native and denatured
states in variant and sporadic CJD PrPSc. In contrast to the
more complex curves obtained using the original Sarkosyl ex-
tracts (Fig. 1), CDI of Sarkosyl-insoluble fractions from the
CJD brain produced simple sigmoidal curves, with the major
transition occurring between guanidine concentrations of 1 M
and 3 M (Fig. 3). Comparison of three cases of variant CJD to
three cases of sporadic CJD (MM1 subtype) showed that the
curves were of the same general shape, but the curve for
variant CJD was displaced to the left, indicating that variant
CJD PrPSc is less stable than sporadic CJD of the MM1 sub-
type. Differences between the variant CJD and sporadic CJD
MM1 subtype curves were significant for the 1.5 M and 2.0 M
readings, with P values of 	0.001. Similar analysis of the curve
for a single typical case of sporadic CJD (VV2 subtype)
showed close similarity to the curve for the MM1 subtype (Fig.
3). The guanidine-induced transition can be usefully expressed
as a GdnHCl1/2 value, the GdnHCl concentration required to
denature half of the PrPSc molecules present in a sample (21,
37). Analysis of replicate samples obtained from three different
cases gave values of 2.344 (standard deviation [SD], 0.159)
for sporadic CJD (MM1 subtype) and 1.678 (SD, 0.175) for
variant CJD. Further analysis of a larger group of variant and
sporadic CJD cases (n 
 10) using the guanidine concentra-
tions where the major transition occurred (1.5 M and 2.0 M)
FIG. 2. Distribution of PrPC and PrPSc after Sarkosyl extraction
and centrifugation. Brain homogenates from the frontal cortex were
prepared, and the supernatants and resuspended pellets were analyzed
by CDI (A and B) and by Western blotting (C). (A) Distribution of
PrPC in supernatants and pellets. The amounts of PrPC in the native
state were determined by CDI, and the relative distribution of PrPC
between supernatants (gray bars) and pellets (black bars) was ex-
pressed as a percentage. (B) Comparison of D/N ratios among initial
brain homogenates, supernatants, and pellets. TRF counts of dena-
tured samples were divided by the counts in the corresponding native
samples to give D/N ratios. White bars, brain homogenates; gray bars,
supernatants; black bars, pellets. (A and B) Data shown represent the
average values  SD obtained for three different cases. The vCJD and
sCJD cases were all of the PRNP codon 129 MM genotype, whereas
the three non-CJD cases are MM, MV, and VV at PRNP codon 129,
respectively. (C) The supernatants (Sup) and pellets (Pel) obtained
after Sarkosyl extraction and centrifugation were treated with protein-
ase K, and the distribution of PrPres was investigated by Western
blotting, using MAb 3F4.
FIG. 3. GdnHCl-induced denaturation of PrPSc from the frontal
cortices of vCJD and sCJD brains. The extent of unfolding of PrPSc
between native (0 M) and denatured (7 M) states was investigated by
CDI. The denatured fraction of PrPSc in each concentration of
GdnHCl was calculated. In vCJD (white squares) and sCJD subtype
MM1 (black diamonds), data represent the average values  SD for
three individuals (two to three samples obtained from each individual).
Data for VV2 sCJD (black triangles) was based on the examination of
one sample in one case. The result for each sample was obtained by use
of one to four independent experiments performed in triplicate.
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showed that the stability difference is a robust general phe-
nomenon (at 1.5 M, P value of 	0.001; at 2.0 M, P value of
	0.0001), although case-to-case variation is evident (Fig. 4).
The structural transition of PrPSc may, in principle, be an
intrinsic property of PrP or may be affected by other compo-
nents present in the samples under testing. Analysis of the
vCJD cerebellum and thalamus (Fig. 5A) showed that PrPSc
present in these regions produced curves similar in shape to
those obtained when analyzing the frontal cortex (Fig. 3). The
GdnHCl1/2 value of the cerebellum (1.643; SD, 0.016) was
very close to that of frontal cortex (1.678; SD, 0.175); how-
ever, the value of the thalamus was somewhat lower (1.445;
SD, 0.159). Statistical analysis of the values obtained at the
1.5 M and 2.0 M guanidine readings confirmed that none of
these pairwise comparisons achieved significance (P values 
0.05), although differences between the thalamus and the other
two regions approached significance at the 2.0 M reading, with
P values for the frontal cortex compared to those for the
thalamus and cerebellum of 0.079 and 0.056, respectively. Plot-
ting these individual values shows that although the mean
values obtained between the vCJD frontal cortex and the vCJD
thalamus differ, the thalamic values fall within the range de-
fined by the values of the frontal cortex samples as a whole
(Fig. 5B). Pairwise comparison of these groups confirmed that
any differences between values obtained for different regions
of the variant CJD brain were not significant (P value  0.1),
whereas the comparison of the variant CJD frontal cortex and
sporadic CJD (MM1 subtype or MM1 subtype plus VV2 sub-
type) frontal cortex values was significantly different (P value	
0.0001).
The conformation-dependent immunoassay as employed
here specifically relates to conformational stability, as mea-
sured by access to the 3F4 epitope, whereas the conformation
stability assay (CSA) employs concentration-dependent guani-
dine denaturation followed by proteinase K (PK) digestion,
thus providing a measure of the stability of the protease-resis-
tant core of PrP to guanidine-induced denaturation. CSA con-
firmed the reduced stability of PrP found in vCJD cases com-
pared to that of PrP found in sporadic CJD (MM1) cases, with
an estimated difference of approximately 0.5 M GdnHCl be-
tween the vCJD and sCJD values, as judged by Western blot-
ting (Fig. 6).
Lastly, we examined the CDI properties of PrPSc from two
cases of Gerstmann-Straussler-Scheinker disease that differed
in their PrPres Western blot profiles, although both carried the
P102L mutation linked to methionine at codon 129. Both pro-
duced simple sigmoidal curves (Fig. 7), but the case that was
FIG. 4. Denatured fractions of PrPSc after treatment with 1.5 M or
2 M GdnHCl. Frontal cortex samples obtained from 10 vCJD and 10
sCJD MM1 subtype cases were treated with different concentrations of
GdnHCl (0 M, 1.5 M, 2 M, and 7 M) and tested by CDI. The denatured
fraction of PrPSc in each concentration of GdnHCl was calculated, and
the results for individual cases were plotted against the concentration
of GdnHCl. The results for the vCJD cases are depicted as gray
diamonds, and the results for the sCJD MM1 cases are depicted as
black diamonds.
FIG. 5. GdnHCl-induced denaturation of PrPSc from the cerebel-
lums and thalami of vCJD cases. (A) Extracts of cerebellums and
thalami from vCJD cases were centrifuged, and the resultant pellets
were exposed to increasing concentrations of GdnHCl. The degree of
unfolding of PrPSc was measured by CDI, and the denatured fraction
of PrPSc was calculated (empty squares, cerebellum; filled squares,
thalamus). Data shown represent the average values  SD for three
individuals. The result for the cerebellum was an average value from
three independent experiments in triplicate, and the result for the
thalamus was an average value from a one-time experiment in tripli-
cate. (B) Based on denaturation profiles shown in panel A and Fig. 3,
the GdnHCl1/2 values were interpolated using the best fit of a second-
order polynomial curve in Excel. Each symbol represents the value of
an individual sample (vCJD, gray; sCJD, black). The results for three
vCJD cases (diamonds, vCJD1; squares, vCJD2; triangles, vCJD3) and
four sCJD cases (diamonds, MM1-1; squares, MM1-2; triangles,
MM1-3; circles, VV2) are shown. The GdnHCl1/2 values of five sam-
ples (three FC samples, one cerebellum [Cb] sample, and one thala-
mus [Th] sample) in each vCJD case, two FC samples in each case of
sCJD MM1 subtype, and one FC sample of a sCJD subtype VV2 case
are depicted.
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characterized by type 1 PrPres had a more stable PrPSc than
that which produced a predominantly 8-kDa PrPres, with
GdnHCl1/2 values of 2.399 M and 1.877 M, respectively.
DISCUSSION
Definitions of PrPSc. The accumulation of abnormal prion
protein (PrPSc) is the only unambiguous marker of TSE or
prion diseases established to date; however, the exact biochem-
ical definitions of the forms of PrPSc most closely associated
with infectivity and neurotoxicity and which might encipher the
agent strain are incompletely defined at present. Operational
definitions of PrPSc have included insolubility in nondenatur-
ing detergents, affinity for particular ligands (including PrPSc-
specific antibodies), and selective precipitation with polyoxo-
metalates, in addition to resistance to proteolytic degradation
(for examples, see references 19, 20, 22, 29, and 31). The last
of these has been thoroughly exploited to the extent that the
terms protease-resistant prion protein (PrPres) and disease-
associated prion protein (PrPSc) are sometimes used inter-
changeably. The finding that a significant proportion of PrPSc
found in the sCJD brain is protease sensitive (44) clearly im-
plies that assays based on PrPres may be an incomplete descrip-
tion of the structural diversity of PrPSc.
Methodological considerations. The conformation-depen-
dent immunoassay (CDI) is an alternative approach to assess-
ing conformational differences between PrPC and PrPSc and a
tool to investigate the potentially strain-related properties of
PrPSc. This approach avoids proteolysis, instead exploiting the
chaotropic salt guanidine hydrochloride (GdnHCl) to unmask
epitopes hidden in PrPSc. Chaotropic agents like GdnHCl dis-
rupt hydrogen bonds that are responsible for the secondary
structure (-helices and -sheets) of proteins (47). Since hy-
drogen bonding also helps maintain tertiary and quaternary
structures of proteins, chaotropic agents can also affect these
structural aspects. Thus, GdnHCl-induced denaturation of
PrPSc molecules may occur at the following two different struc-
tural levels: loss of secondary structure (i.e., uncoiled into an
irregularly coiled polypeptide) and loss of quaternary structure
(i.e., dissociation of PrPSc aggregates).
In a previous study that examined the dissociation/unfolding
pathways of PrPSc in hamster prion strains during exposures to
ascending concentrations of GdnHCl (42), the GdnHCl-in-
duced denaturation of PrPSc molecules was reported to consist
of the following stepwise pathway: aggregates 3 dissociated
folded monomer 3 partially unfolded intermediate 3 un-
folded monomer. The dissociation of PrPSc aggregates into folded
monomers occurred with the midpoint of transition at 1.5 to
2.0 M GdnHCl, followed by the state of stable intermediate
(midpoint of transition, 3.5 M GdnHCl). Given that the
hidden recognition site of MAb 3F4 becomes accessible in
most of PrPSc molecules following incubation with 3 M
GdnHCl, the degree of unfolding of PrPSc molecules measured
by CDI most likely reflects the degree of dissociation of ag-
gregated PrPSc. However, the loss of -sheet structure follow-
ing incubation with GdnHCl may also contribute to the CDI-
based denaturation profiles, since the region with the 3F4
epitope has been proposed to acquire high -sheet content
during the conversion of PrPC into PrPSc (15), and the acqui-
sition of -sheet structure is thought to make the 3F4 epitope
inaccessible (43). Despite these speculations, the exact mech-
anism by which GdnHCl denatures PrPSc remains elusive (25),
and the presence of detergents such as N-lauroylsarcosinate
sodium salt (Sarkosyl) may also interfere with the tertiary and
quaternary structures of PrPSc aggregates by disrupting hydro-
phobic interactions (47). The detection monoclonal antibody
used in CDI is MAb 3F4, which recognizes residues 109 to 112
of human PrP, and therefore, the conformational stability of
PrPSc measured by CDI is thought to represent that of the N
terminus of PrP (18, 43). The N-terminal region of PrPSc en-
compassing the 3F4 epitope was found to be critical in retain-
FIG. 7. Comparison of denaturation profiles between two GSS
cases with different PrPres patterns. The PrPSc denaturation profile
from a GSS case with typical three-band PrPres (empty squares) was
compared with that from a GSS case with lower-molecular-weight
PrPres only (filled squares). The extent of unfolding of PrPSc between
native (0 M) and denatured (7 M) states was determined by CDI. Data
shown represent average values  SD from three independent exper-
iments in triplicate.
FIG. 6. Conformation stability assay of PrPres from frontal cortices
of vCJD and MM1 sCJD cases. Western blot analysis of PrPres from
vCJD and sCJD MM1 brain samples treated with increasing concen-
trations of GdnHCl (0 to 4 M, as indicated) and then subjected to
proteinase K digestion at the concentration of 20 g/ml for 1 h at 37°C
() or allowed to remain undigested. After methanol precipitation of
the protein, samples were analyzed by Western blotting using the
anti-PrP MAb 3F4. Molecular mass markers (M) are shown, and they
are labeled with their molecular mass in kDa. The result shown is
representative of two independent experiments, with samples from two
different cases of vCJD and sCJD (MM1).
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ing infectivity in the Chandler mouse-adapted scrapie strain
(45) and has also been implicated in relatively low infectivity
associated with synthetic prions (3, 23).
Although the conformational stability assay (CSA) shares
features with the CDI (notably, GdnHCl-induced denaturation
and 3F4 detection), it is important to recognize that the CSA
does not assess the stability of protease-sensitive PrPSc, al-
though it does give an indication of the stability of the PrP
molecule as a whole, by virtue of the size of the protease-
resistant fragments seen on Western blots. For these reasons,
we have primarily used the CDI (using the CSA as a confir-
matory assay) to directly examine whether PrPSc associated
with different human prion diseases differs in its conforma-
tional stability.
Stability differences identified by CDI. Previous studies of
the conformational stability of PrPSc using the CDI have been
restricted to the analysis of animal prion diseases (scrapie) in
the form of rodent-adapted strains in hamsters and mice (43,
49). To date, no equivalent studies have been published using
human prion strains transmitted to rodents, nor has the po-
tential been explored for the CDI to distinguish between the
forms of PrPSc found in different human prion diseases.
Our results using postmortem brain tissue from representa-
tive cases of sCJD and vCJD show that PrPSc in the most
commonly occurring MM1 subtype of sCJD is demonstrably
more resistant to GdnHCl-induced denaturation than that in
vCJD, as judged by CDI and the 3F4 epitope. This observation
is supported by similar findings using the CSA, in which the
method to measure conformational stability differs. In princi-
ple, such a conformation difference might be attributable to
the same molecular property that is responsible for the West-
ern blot type 1/type 2 PrPres difference; however, the sCJD
VV2 subtype case examined here shared the conformational
stability of the MM1 sCJD case, and not that of the vCJD
(MM2B) case, suggesting that the conformational stability as
measured by CDI is based on a property (or properties) of
PrPSc that is different from the property of PrPres that deter-
mines the Western blot type.
Although the difference between sCJD and vCJD is clear
and reproducible, we did observe a degree of intersample and
intercase variability. This may reflect genuine microheteroge-
neity in PrPSc stability, or it may reflect confounding factors
associated with cellular and molecular properties of the tissue
sampled. Regional analysis of the vCJD brain showed that
although the stability measurements of the frontal cortex and
cerebellum were closely similar when expressed as average
values, the equivalent measurement of the thalamus gave a
lower GdnHCl1/2 value. This is intriguing because the pathol-
ogy of the vCJD thalamus, including the PrP immunostaining
pattern, is highly characteristic and differs from that of the
cerebrum and cerebellum. However, the individual values for
the vCJD thalamus fall within the range of individual values for
the vCJD frontal cortex, so it is unclear at present what signif-
icance this observation may have.
The additional analysis of two GSS cases (both of the PRNP
P102L codon 129 M genotype) that differ radically in their
PrPres Western blot profiles showed that they too could be
distinguished by the stability of PrPSc when measured by the
access to the 3F4 epitope by CDI. The stability of PrPSc in the
GSS case characterized by type 1 PrPres was similar to the stability
of that in the sCJD cases, whereas the stability of PrPSc in the case
in which proteinase K digestion and Western blotting produced
bands of much smaller sizes (8 kDa) was found to be similar to
the stability of that in the vCJD cases.
Although this study examined the stability of the “detergent-
insoluble” fraction of PrP and was conducted in a limited
number of disease phenotypes and/or cases, taken together,
the results suggest that the structural stability of PrPSc as de-
termined by CDI is not uniform among human prion diseases
and that at least two stability states exist, which are at least
partly independent of the conventional Western blot PrPres
type (fragment size and glycoform ratio) and the PRNP geno-
type (pathogenic mutations and codon 129). Having now de-
fined the GdnHCl concentration range at which the major
structural transition occurs in CJD and GSS cases, it will be
important to try to refine these methods to establish whether
further meaningful distinctions can be made between examples
of the full range of human prion diseases, including all of the
subtypes of sCJD, fatal familial insomnia, and the more re-
cently described protease-sensitive prionopathy (12).
Our proposal is not without precedent. Comparison of single
cases of sCJD and vCJD using PrPSc-specific peptide capture
followed by examination with sandwich ELISA has shown a
higher stability for sCJD PrPSc (21). In their study, the differ-
ence in GdnHCl1/2 values was 0.6 M between the two forms
of CJD (GdnHCl1/2 in vCJD, 1.85 M; GdnHCl1/2 in MM1
sCJD, 2.45 M), which resembles the values obtained using a
greater number of vCJD and sCJD cases and the CDI in this
study. CSA analysis of PrPres in sCJD of the MM genotype has
shown that type 1 PrPres is more stable than type 2 (7), and this
observation has been extended using a rapid dot blot variation
of the CSA to encompass the MV and VV genotypes in spo-
radic CJD cases (53). Moreover, a recent conference abstract
suggests that this higher structural stability of sCJD MM1
(compared to that of sCJD MM2) is conserved when these
diseases are transmitted to bank voles (40). When GdnHCl1/2
values have been given in those papers, we have compared
them with our own results (Table 1). Given that the experi-
TABLE 1. Comparison of the GdnHCl1/2 values of PrP
Sc obtained in this study with those published previously
Technique
GdnHCl1/2 value of PrPSc ina:
Material analyzed Reference
vCJD sCJD MM1 sCJD MM2A sCJD VV2A
CDI 1.678 2.344 ND 2.308 Human brain This study
PrPSc-specific capture 1.850 2.450 ND ND Human brain 21
CSA ND 2.760 1.420 ND Human brain 7
Detergent insolubility ND 2.950 1.460 2.690 Bank vole brain 40
a ND 
 not determined.
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mental approaches differed markedly between those studies,
there is a surprising degree of agreement between some of
them. Where discrepancies exist, it is unclear whether these
result from differences in the methodology employed (such as
the use of CDI measurements of PrPSc or CSA measurement
of PrPres), intersample or intercase variability, or some other
factor.
Biological significance of PrPSc stability. There is accumu-
lating experimental evidence to suggest that the conforma-
tional stability of PrPSc has biological significance. Conforma-
tional stability was used as an argument to defend the original
description of synthetic prions (23) against the criticism that
they could have resulted from inadvertent contamination with
common laboratory strains. The GdnHCl1/2 values of mouse
PrPSc resulting from infection with synthetic prions differed
from those of the commonly used RML strain (24). Further
passage of synthetically derived prion resulted in two distinct
strains that were found to differ in both incubation period and
PrPSc stability, thus prompting an evaluation of the relation-
ship between stability (as judged by PrPSc GdnHCl1/2 values
measured by CSA) and incubation period in mice generally
(25). A strong positive correlation between higher stability and
longer incubation periods was found (25). The hypothesis that
incubation time is a function of PrPSc stability (in addition to
the known factors such as titer, route, and PrP expression level
and sequence) was further tested by artificially producing an
array of synthetic PrP amyloids differing in their conforma-
tional stability and then by testing their biological properties
(9). The results showed that more labile PrPSc conformations
correlated with faster replication, shorter incubation periods,
and a degree of strain instability. How such considerations
might relate to human prion diseases is unclear at this time.
However, the finding that vCJD PrPSc is less intrinsically stable
than that of sCJD may be interpreted as a further reason for
concern regarding the potential for secondary transmission of
the promiscuous BSE/vCJD prion strain.
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